AMT-260
Temporal Lobe Epilepsy / Mesial Temporal Lobe Epilepsy
PreclinicalResearch
Key Facts
Indication
Temporal Lobe Epilepsy / Mesial Temporal Lobe Epilepsy
Phase
Preclinical
Status
Research
Company
About uniQure
uniQure is a clinical-stage gene therapy company with over two decades of experience, dedicated to reimagining medicine through innovative genomic treatments. The company has built a modular AAV platform, featuring proprietary technologies like miQURE for gene silencing, and is advancing a pipeline targeting CNS and liver diseases. With a lead program, AMT-130, in late-stage development for Huntington's disease and a commercial-stage partnership for hemophilia B gene therapy, uniQure is positioned at the forefront of the gene therapy revolution.
View full company profile